Izotropic Announces Private Placement to Raise Up to $150K
News related to:Izotropic Corporation · 1 min read
Izotropic Corporation, a medical device company commercializing IzoView, a dedicated breast CT imaging system, has announced a non-brokered private placement to raise up to $150,000. The company plans to issue 750,000 units at a price of $0.20 per unit, each consisting of one common share and one transferable warrant.
Each warrant will allow the holder to purchase one additional share at $0.30 per share for a period of three years from the closing of the offering. The funds raised will be used for general working capital.
According to the release, all securities issued in connection with the offering will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable securities legislation. The offering is subject to receipt of all necessary regulatory approvals.
The company emphasizes that none of the securities issued in the offering will be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act.
Izotropic Corporation, based in Vancouver, British Columbia, and Casablanca, Morocco, is focused on advancing its IzoView technology for more accurate screening and diagnosis of breast cancers. The company's latest move aims to bolster its financial resources to support ongoing research and development efforts.
The private placement is part of the company's strategy to secure additional capital to fund its operations and expand its market reach. Izotropic's management believes that the additional capital will help the company to continue its mission of improving breast cancer detection and treatment outcomes.
The release notes that the offering is intended to be completed with a strategic investor. The company did not disclose the identity of the investor but stated that the investor is committed to supporting Izotropic's mission.
The press release was issued on September 25, 2026, in Vancouver, British Columbia, and Casablanca, Morocco.